One approach was developing an integrin α2β1‐targeting H ferritin for glioma treatment, that showed enhanced doxorubicin loading capacity and tumor targeting capability after crossing the blood–brain barrier (Huang et al. 2021; Table 1). The gene discussed is FTH1; the disease is neoplasm.